摘要
目的观察急性冠状动脉综合征(ACS)患者血清高敏C-反应蛋白(Hs-CRP)、血脂水平变化及血脂康的干预情况。方法69例ACS患者随机分为血脂康组(40例)和常规治疗组(29例),治疗前后分别测定Hs-CRP、总胆固醇、甘油三酯、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C);另30名健康人为对照组。结果与对照组比较,ACS患者Hs-CRP水平明显升高,且与心肌损害程度密切相关。血脂康治疗2周,能明显下调ACS患者的Hs-CRP水平。结论血清Hs-CRP水平与ACS的发生、严重程度密切相关,血脂康的抗炎作用在ACS的早期治疗中有重要意义。
Objective To observe the levels of Hs-CRP and lipoproteins of ACS patients and the effects of Xuezhikang. Methods Sixty-nine ACS patients were randomly divided into Xuezhikang group （40 cases ） and routine group （29 cases）, other 30 healthy cases as control group. Before and after the treatment, the levels of Hs-CRP,TC ,TG, LDL-C, HDL-C were detected. Results Comparing to control group, the Hs-CRP level of ACS patients was significantly increased and related to myocardial injury. After 2 weeks treating with Xuezhikang, the Hs-CRP level of ACS patients was significantly decreased. Conclusion The Hs-CRP level was related to ACS, the anti-inflammation of Xuezhikang had significantly effect during the treatment of ACS patients.
出处
《中国心血管病研究》
CAS
2007年第6期444-446,共3页
Chinese Journal of Cardiovascular Research
